Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematologic Neoplasms | 41 | 2024 | 336 | 12.060 |
Why?
|
Germ-Line Mutation | 38 | 2024 | 341 | 10.680 |
Why?
|
Genetic Predisposition to Disease | 48 | 2024 | 2322 | 7.650 |
Why?
|
Leukemia, Myeloid, Acute | 41 | 2024 | 782 | 6.210 |
Why?
|
Myelodysplastic Syndromes | 33 | 2024 | 351 | 6.190 |
Why?
|
DNA Methylation | 42 | 2023 | 656 | 5.300 |
Why?
|
Myeloproliferative Disorders | 13 | 2024 | 132 | 4.670 |
Why?
|
Proto-Oncogene Proteins | 25 | 2022 | 661 | 3.400 |
Why?
|
Cytosine | 18 | 2020 | 128 | 3.380 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 17 | 2022 | 60 | 3.060 |
Why?
|
Hematopoiesis | 20 | 2023 | 164 | 2.810 |
Why?
|
5-Methylcytosine | 19 | 2022 | 113 | 2.760 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 12 | 2023 | 55 | 2.690 |
Why?
|
Leukemia | 13 | 2023 | 321 | 2.580 |
Why?
|
Hematopoietic Stem Cell Transplantation | 25 | 2023 | 884 | 2.450 |
Why?
|
Neoplasms | 18 | 2024 | 3009 | 2.330 |
Why?
|
Genetic Testing | 12 | 2024 | 538 | 2.320 |
Why?
|
Epigenesis, Genetic | 22 | 2020 | 502 | 2.150 |
Why?
|
Leukemia, Myeloid | 11 | 2023 | 249 | 2.150 |
Why?
|
High-Throughput Nucleotide Sequencing | 7 | 2024 | 478 | 2.110 |
Why?
|
Germ Cells | 18 | 2024 | 130 | 2.020 |
Why?
|
Humans | 198 | 2024 | 88611 | 1.990 |
Why?
|
Neuroblastoma | 9 | 2022 | 394 | 1.950 |
Why?
|
BRCA1 Protein | 4 | 2024 | 202 | 1.940 |
Why?
|
DNA-Binding Proteins | 20 | 2020 | 1240 | 1.720 |
Why?
|
Gene Expression Regulation, Neoplastic | 21 | 2022 | 1256 | 1.690 |
Why?
|
Mutation | 37 | 2024 | 4097 | 1.650 |
Why?
|
Hematopoietic Stem Cells | 12 | 2023 | 299 | 1.550 |
Why?
|
Dioxygenases | 16 | 2020 | 75 | 1.530 |
Why?
|
Blood Donors | 3 | 2016 | 24 | 1.510 |
Why?
|
Mixed Function Oxygenases | 4 | 2022 | 69 | 1.490 |
Why?
|
Thrombocytopenia | 6 | 2021 | 185 | 1.470 |
Why?
|
CpG Islands | 11 | 2020 | 158 | 1.380 |
Why?
|
DNA Copy Number Variations | 2 | 2020 | 177 | 1.380 |
Why?
|
DEAD-box RNA Helicases | 5 | 2023 | 64 | 1.370 |
Why?
|
Transplantation Conditioning | 21 | 2023 | 373 | 1.230 |
Why?
|
Graft vs Host Disease | 10 | 2023 | 358 | 1.170 |
Why?
|
Histones | 10 | 2023 | 327 | 1.160 |
Why?
|
Azacitidine | 11 | 2020 | 139 | 1.150 |
Why?
|
DNA Mutational Analysis | 9 | 2016 | 531 | 1.130 |
Why?
|
Anemia, Aplastic | 3 | 2023 | 32 | 1.130 |
Why?
|
Proto-Oncogene Proteins c-ets | 4 | 2022 | 25 | 1.120 |
Why?
|
Neoplasms, Second Primary | 6 | 2024 | 258 | 1.070 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2010 | 173 | 1.070 |
Why?
|
Bone Marrow | 5 | 2023 | 445 | 1.050 |
Why?
|
Lymphoma | 6 | 2016 | 264 | 0.960 |
Why?
|
Alleles | 5 | 2021 | 1132 | 0.930 |
Why?
|
Cell Transformation, Neoplastic | 7 | 2023 | 447 | 0.930 |
Why?
|
Proto-Oncogene Proteins c-myc | 3 | 2020 | 126 | 0.930 |
Why?
|
Nuclear Proteins | 8 | 2015 | 726 | 0.880 |
Why?
|
N-Myc Proto-Oncogene Protein | 2 | 2022 | 38 | 0.870 |
Why?
|
Female | 78 | 2024 | 45759 | 0.840 |
Why?
|
Hypoxia-Inducible Factor 1 | 1 | 2022 | 43 | 0.820 |
Why?
|
Leukemia, Erythroblastic, Acute | 2 | 2021 | 30 | 0.820 |
Why?
|
Repressor Proteins | 5 | 2021 | 419 | 0.810 |
Why?
|
Globins | 1 | 2021 | 31 | 0.810 |
Why?
|
Genome, Human | 6 | 2022 | 767 | 0.780 |
Why?
|
Neoplastic Stem Cells | 3 | 2016 | 160 | 0.780 |
Why?
|
Genetic Association Studies | 4 | 2021 | 294 | 0.760 |
Why?
|
Receptors, Colony-Stimulating Factor | 1 | 2020 | 5 | 0.760 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 157 | 0.760 |
Why?
|
Transcription Factors | 10 | 2020 | 1647 | 0.740 |
Why?
|
Cell Line, Tumor | 20 | 2022 | 2538 | 0.730 |
Why?
|
Breast Neoplasms | 5 | 2024 | 2980 | 0.730 |
Why?
|
Myeloid Cells | 5 | 2017 | 100 | 0.700 |
Why?
|
Adult | 51 | 2024 | 26348 | 0.700 |
Why?
|
Cell Differentiation | 10 | 2017 | 1518 | 0.700 |
Why?
|
Xeroderma Pigmentosum | 1 | 2019 | 9 | 0.690 |
Why?
|
Male | 68 | 2024 | 42012 | 0.680 |
Why?
|
Animals | 47 | 2023 | 27233 | 0.680 |
Why?
|
Erythropoiesis | 3 | 2013 | 51 | 0.670 |
Why?
|
DNA Modification Methylases | 4 | 2022 | 28 | 0.660 |
Why?
|
Ovarian Neoplasms | 2 | 2024 | 759 | 0.660 |
Why?
|
Precision Medicine | 2 | 2021 | 407 | 0.650 |
Why?
|
Promoter Regions, Genetic | 13 | 2020 | 956 | 0.650 |
Why?
|
Antineoplastic Agents | 11 | 2022 | 2406 | 0.650 |
Why?
|
Aged | 51 | 2024 | 18932 | 0.640 |
Why?
|
Antimetabolites, Antineoplastic | 6 | 2017 | 237 | 0.620 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 393 | 0.610 |
Why?
|
Transplantation, Homologous | 23 | 2023 | 1001 | 0.600 |
Why?
|
BRCA2 Protein | 3 | 2024 | 159 | 0.600 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2016 | 50 | 0.600 |
Why?
|
Genes, Tumor Suppressor | 6 | 2018 | 159 | 0.580 |
Why?
|
Blood Platelet Disorders | 2 | 2021 | 9 | 0.580 |
Why?
|
Regulatory Sequences, Nucleic Acid | 2 | 2017 | 153 | 0.580 |
Why?
|
Disease Susceptibility | 4 | 2023 | 199 | 0.570 |
Why?
|
Lymphoma, B-Cell | 2 | 2020 | 105 | 0.570 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2017 | 612 | 0.560 |
Why?
|
X Chromosome Inactivation | 2 | 2015 | 28 | 0.540 |
Why?
|
Cord Blood Stem Cell Transplantation | 5 | 2016 | 89 | 0.520 |
Why?
|
Prognosis | 21 | 2022 | 3750 | 0.520 |
Why?
|
Mice | 33 | 2021 | 11710 | 0.510 |
Why?
|
Models, Biological | 5 | 2021 | 1764 | 0.510 |
Why?
|
Chromosomes, Human, X | 1 | 2015 | 55 | 0.510 |
Why?
|
Pedigree | 9 | 2024 | 968 | 0.500 |
Why?
|
Consensus | 2 | 2022 | 352 | 0.500 |
Why?
|
Apolipoproteins E | 1 | 2015 | 130 | 0.500 |
Why?
|
Donor Selection | 1 | 2015 | 76 | 0.500 |
Why?
|
RNA, Messenger | 9 | 2023 | 2009 | 0.490 |
Why?
|
Tumor Suppressor Proteins | 2 | 2014 | 289 | 0.490 |
Why?
|
Cell Proliferation | 8 | 2018 | 1647 | 0.480 |
Why?
|
Preleukemia | 1 | 2014 | 11 | 0.480 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2017 | 138 | 0.480 |
Why?
|
Isocitrate Dehydrogenase | 5 | 2023 | 54 | 0.470 |
Why?
|
Clonal Evolution | 1 | 2014 | 15 | 0.470 |
Why?
|
Intercellular Signaling Peptides and Proteins | 3 | 2022 | 182 | 0.470 |
Why?
|
Erythroid Cells | 1 | 2013 | 14 | 0.470 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2012 | 470 | 0.470 |
Why?
|
fms-Like Tyrosine Kinase 3 | 5 | 2023 | 131 | 0.470 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2021 | 409 | 0.460 |
Why?
|
DNA Repair Enzymes | 1 | 2014 | 55 | 0.460 |
Why?
|
Epigenomics | 5 | 2019 | 103 | 0.460 |
Why?
|
Genetic Variation | 5 | 2022 | 1369 | 0.460 |
Why?
|
Genomics | 9 | 2024 | 747 | 0.460 |
Why?
|
Middle Aged | 50 | 2024 | 25699 | 0.460 |
Why?
|
Stem Cell Transplantation | 4 | 2012 | 188 | 0.450 |
Why?
|
Dacarbazine | 1 | 2014 | 102 | 0.450 |
Why?
|
Checkpoint Kinase 2 | 2 | 2024 | 26 | 0.450 |
Why?
|
Antigens, CD34 | 10 | 2017 | 158 | 0.450 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 4 | 2021 | 21 | 0.440 |
Why?
|
Sex Characteristics | 1 | 2015 | 321 | 0.440 |
Why?
|
Mitoxantrone | 4 | 2020 | 68 | 0.440 |
Why?
|
Haploinsufficiency | 2 | 2013 | 63 | 0.440 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 2 | 2024 | 53 | 0.440 |
Why?
|
Bone Marrow Cells | 3 | 2017 | 261 | 0.440 |
Why?
|
Hypoxia | 4 | 2022 | 650 | 0.440 |
Why?
|
Disease Management | 4 | 2024 | 328 | 0.430 |
Why?
|
Karyopherins | 1 | 2012 | 14 | 0.430 |
Why?
|
Chromosome Deletion | 4 | 2011 | 229 | 0.430 |
Why?
|
GATA2 Transcription Factor | 4 | 2023 | 14 | 0.420 |
Why?
|
Induction Chemotherapy | 2 | 2018 | 149 | 0.420 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2018 | 2536 | 0.420 |
Why?
|
Colon | 1 | 2015 | 505 | 0.420 |
Why?
|
Histone Code | 1 | 2012 | 19 | 0.410 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2012 | 124 | 0.400 |
Why?
|
Young Adult | 22 | 2024 | 6218 | 0.390 |
Why?
|
Colonic Neoplasms | 1 | 2015 | 566 | 0.380 |
Why?
|
Tissue Donors | 3 | 2012 | 501 | 0.380 |
Why?
|
Burkitt Lymphoma | 1 | 2010 | 32 | 0.370 |
Why?
|
Sulfones | 2 | 2023 | 45 | 0.360 |
Why?
|
Hematology | 2 | 2020 | 30 | 0.360 |
Why?
|
Mediastinal Neoplasms | 1 | 2010 | 47 | 0.360 |
Why?
|
Histone Deacetylase Inhibitors | 4 | 2017 | 92 | 0.360 |
Why?
|
Antibodies, Neoplasm | 6 | 2010 | 84 | 0.360 |
Why?
|
Acute Disease | 11 | 2022 | 838 | 0.350 |
Why?
|
Chromosomes, Human, Pair 5 | 5 | 2021 | 109 | 0.350 |
Why?
|
Cell Hypoxia | 3 | 2022 | 170 | 0.340 |
Why?
|
Biomarkers | 4 | 2021 | 1759 | 0.340 |
Why?
|
Cell-Free Nucleic Acids | 2 | 2021 | 82 | 0.340 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2011 | 80 | 0.340 |
Why?
|
Adenocarcinoma | 2 | 2015 | 1184 | 0.330 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2009 | 86 | 0.330 |
Why?
|
Base Sequence | 10 | 2019 | 2331 | 0.330 |
Why?
|
Genetic Counseling | 3 | 2021 | 101 | 0.330 |
Why?
|
Abnormalities, Multiple | 1 | 2010 | 234 | 0.320 |
Why?
|
Family | 4 | 2016 | 322 | 0.320 |
Why?
|
Mastocytosis | 1 | 2008 | 13 | 0.320 |
Why?
|
Telomerase | 3 | 2020 | 61 | 0.320 |
Why?
|
Gene Expression Profiling | 9 | 2017 | 1427 | 0.320 |
Why?
|
Transcriptional Activation | 2 | 2020 | 290 | 0.320 |
Why?
|
RNA Splicing | 2 | 2015 | 150 | 0.310 |
Why?
|
DNA | 2 | 2011 | 1308 | 0.310 |
Why?
|
Aged, 80 and over | 19 | 2023 | 6723 | 0.310 |
Why?
|
Aging | 3 | 2023 | 712 | 0.300 |
Why?
|
HMGA2 Protein | 1 | 2007 | 14 | 0.300 |
Why?
|
Adolescent | 18 | 2024 | 9157 | 0.300 |
Why?
|
Cytarabine | 4 | 2020 | 219 | 0.300 |
Why?
|
Cell Line | 5 | 2021 | 2498 | 0.300 |
Why?
|
MicroRNAs | 2 | 2015 | 551 | 0.300 |
Why?
|
Treatment Outcome | 18 | 2018 | 8178 | 0.290 |
Why?
|
Translocation, Genetic | 4 | 2021 | 266 | 0.280 |
Why?
|
Leukemia, Promyelocytic, Acute | 2 | 2018 | 49 | 0.280 |
Why?
|
Risk Assessment | 3 | 2015 | 2286 | 0.270 |
Why?
|
Age of Onset | 3 | 2024 | 311 | 0.270 |
Why?
|
Penetrance | 2 | 2024 | 45 | 0.270 |
Why?
|
Enzyme Inhibitors | 3 | 2013 | 646 | 0.270 |
Why?
|
Sulfonamides | 2 | 2021 | 318 | 0.270 |
Why?
|
Chromosome Aberrations | 4 | 2021 | 390 | 0.270 |
Why?
|
Biomarkers, Tumor | 4 | 2021 | 1520 | 0.270 |
Why?
|
Telomere | 3 | 2021 | 112 | 0.270 |
Why?
|
DNA (Cytosine-5-)-Methyltransferase 1 | 4 | 2014 | 20 | 0.260 |
Why?
|
Gene Expression Regulation | 5 | 2021 | 1977 | 0.260 |
Why?
|
Clone Cells | 2 | 2023 | 214 | 0.250 |
Why?
|
Survival Analysis | 9 | 2021 | 1542 | 0.250 |
Why?
|
Risk | 4 | 2021 | 660 | 0.250 |
Why?
|
Genes, BRCA2 | 2 | 2024 | 161 | 0.250 |
Why?
|
Pyrimidines | 3 | 2021 | 372 | 0.250 |
Why?
|
Pancytopenia | 2 | 2022 | 23 | 0.250 |
Why?
|
Fusion Proteins, bcr-abl | 3 | 2010 | 108 | 0.250 |
Why?
|
Gene Expression | 5 | 2023 | 1312 | 0.250 |
Why?
|
Risk Factors | 9 | 2021 | 5449 | 0.240 |
Why?
|
RNA Interference | 4 | 2018 | 378 | 0.240 |
Why?
|
Fanconi Anemia Complementation Group N Protein | 1 | 2024 | 14 | 0.240 |
Why?
|
Clinical Decision-Making | 3 | 2022 | 275 | 0.240 |
Why?
|
Mice, Transgenic | 9 | 2013 | 1571 | 0.240 |
Why?
|
Phenotype | 10 | 2022 | 2435 | 0.240 |
Why?
|
Biology | 2 | 2021 | 51 | 0.240 |
Why?
|
Zinc Fingers | 2 | 2023 | 58 | 0.240 |
Why?
|
Prevalence | 3 | 2023 | 1248 | 0.230 |
Why?
|
Remission Induction | 10 | 2020 | 735 | 0.230 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2024 | 73 | 0.230 |
Why?
|
RNA, Small Interfering | 4 | 2018 | 559 | 0.230 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 74 | 0.230 |
Why?
|
Amides | 1 | 2023 | 53 | 0.230 |
Why?
|
Antibodies, Monoclonal | 6 | 2010 | 1402 | 0.230 |
Why?
|
Mice, Inbred C57BL | 10 | 2020 | 3202 | 0.230 |
Why?
|
Gene Frequency | 3 | 2024 | 684 | 0.230 |
Why?
|
Fibroblasts | 3 | 2022 | 755 | 0.230 |
Why?
|
Haplotypes | 3 | 2016 | 637 | 0.230 |
Why?
|
alpha Karyopherins | 1 | 2023 | 10 | 0.230 |
Why?
|
Hematologic Diseases | 2 | 2022 | 78 | 0.230 |
Why?
|
Unrelated Donors | 3 | 2023 | 44 | 0.230 |
Why?
|
Geriatric Assessment | 2 | 2015 | 182 | 0.220 |
Why?
|
Germinal Center | 2 | 2015 | 55 | 0.220 |
Why?
|
Sequence Analysis, DNA | 5 | 2019 | 863 | 0.220 |
Why?
|
Binding Sites | 4 | 2015 | 1113 | 0.220 |
Why?
|
Cell Cycle Proteins | 4 | 2015 | 399 | 0.220 |
Why?
|
Australia | 1 | 2023 | 100 | 0.220 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 112 | 0.220 |
Why?
|
Gene-Environment Interaction | 3 | 2024 | 109 | 0.220 |
Why?
|
Tetrasomy | 1 | 2022 | 3 | 0.210 |
Why?
|
Kaplan-Meier Estimate | 8 | 2018 | 865 | 0.210 |
Why?
|
Neoplasm Proteins | 3 | 2015 | 539 | 0.210 |
Why?
|
Histone Demethylases | 2 | 2023 | 32 | 0.210 |
Why?
|
Adenine Nucleotides | 2 | 2013 | 63 | 0.210 |
Why?
|
Arabinonucleosides | 2 | 2013 | 39 | 0.210 |
Why?
|
Genes, p53 | 4 | 1997 | 109 | 0.210 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2016 | 166 | 0.210 |
Why?
|
Cell Movement | 3 | 2022 | 784 | 0.210 |
Why?
|
Cyclophosphamide | 1 | 2023 | 300 | 0.210 |
Why?
|
Genotype | 4 | 2021 | 1867 | 0.210 |
Why?
|
Mastocytosis, Systemic | 2 | 2014 | 12 | 0.200 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2014 | 154 | 0.200 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2021 | 21 | 0.200 |
Why?
|
HLA Antigens | 2 | 2016 | 226 | 0.200 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2024 | 386 | 0.200 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2012 | 64 | 0.200 |
Why?
|
Quantitative Trait Loci | 3 | 2014 | 606 | 0.200 |
Why?
|
Retinoblastoma-Like Protein p130 | 1 | 2021 | 7 | 0.200 |
Why?
|
Morpholines | 1 | 2021 | 69 | 0.200 |
Why?
|
Megakaryocytes | 1 | 2021 | 36 | 0.190 |
Why?
|
Molecular Sequence Data | 12 | 2015 | 3029 | 0.190 |
Why?
|
Telomere Shortening | 1 | 2021 | 25 | 0.190 |
Why?
|
Fetal Blood | 3 | 2017 | 91 | 0.190 |
Why?
|
Bias | 1 | 2021 | 130 | 0.190 |
Why?
|
Janus Kinase 2 | 2 | 2019 | 60 | 0.190 |
Why?
|
Cysteine | 2 | 2011 | 136 | 0.190 |
Why?
|
Glioma | 1 | 2023 | 291 | 0.190 |
Why?
|
Child | 9 | 2024 | 7089 | 0.180 |
Why?
|
Mice, Knockout | 6 | 2015 | 1988 | 0.180 |
Why?
|
Isoenzymes | 2 | 2012 | 273 | 0.180 |
Why?
|
Fetus | 1 | 2021 | 230 | 0.180 |
Why?
|
Alcohol Oxidoreductases | 1 | 2020 | 17 | 0.180 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2014 | 1945 | 0.180 |
Why?
|
Multiple Myeloma | 2 | 2018 | 326 | 0.180 |
Why?
|
Minority Groups | 1 | 2021 | 140 | 0.180 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 62 | 0.180 |
Why?
|
Mutation, Missense | 3 | 2018 | 276 | 0.180 |
Why?
|
Face | 1 | 2020 | 116 | 0.180 |
Why?
|
Indoles | 1 | 2021 | 310 | 0.170 |
Why?
|
Alternative Splicing | 4 | 2015 | 210 | 0.170 |
Why?
|
Chromosome Disorders | 1 | 2020 | 115 | 0.170 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2021 | 112 | 0.170 |
Why?
|
Proteins | 2 | 2008 | 786 | 0.170 |
Why?
|
Karyotype | 1 | 2019 | 34 | 0.170 |
Why?
|
Molecular Sequence Annotation | 1 | 2019 | 69 | 0.170 |
Why?
|
Carcinogenesis | 2 | 2023 | 207 | 0.170 |
Why?
|
Endodeoxyribonucleases | 1 | 2018 | 11 | 0.160 |
Why?
|
Superoxides | 1 | 2019 | 74 | 0.160 |
Why?
|
Transcription, Genetic | 4 | 2020 | 1156 | 0.160 |
Why?
|
Cognitive Dysfunction | 1 | 2021 | 141 | 0.160 |
Why?
|
Glutarates | 2 | 2023 | 8 | 0.160 |
Why?
|
B-Lymphocytes | 2 | 2015 | 737 | 0.160 |
Why?
|
Muscle Proteins | 1 | 1999 | 134 | 0.160 |
Why?
|
Sequence Analysis, RNA | 2 | 2017 | 230 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2023 | 1352 | 0.160 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2016 | 93 | 0.160 |
Why?
|
Clinical Trials as Topic | 3 | 2018 | 1142 | 0.160 |
Why?
|
Recurrence | 6 | 2023 | 1168 | 0.160 |
Why?
|
Histocompatibility Testing | 3 | 2017 | 138 | 0.160 |
Why?
|
Interleukin-6 | 3 | 2023 | 260 | 0.160 |
Why?
|
Azepines | 2 | 2015 | 23 | 0.160 |
Why?
|
Protein Kinases | 1 | 1999 | 212 | 0.160 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2018 | 8 | 0.160 |
Why?
|
Cytokines | 2 | 2019 | 801 | 0.160 |
Why?
|
Bacterial Physiological Phenomena | 1 | 2018 | 41 | 0.160 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 44 | 0.150 |
Why?
|
Mammary Neoplasms, Experimental | 5 | 1997 | 125 | 0.150 |
Why?
|
Exome | 2 | 2015 | 127 | 0.150 |
Why?
|
Zebrafish Proteins | 5 | 1997 | 146 | 0.150 |
Why?
|
Combined Modality Therapy | 5 | 2017 | 1709 | 0.150 |
Why?
|
Up-Regulation | 3 | 2015 | 729 | 0.150 |
Why?
|
Exons | 3 | 2015 | 452 | 0.150 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 2 | 2014 | 35 | 0.150 |
Why?
|
Genes, Dominant | 1 | 2017 | 117 | 0.150 |
Why?
|
Antibodies, Monoclonal, Humanized | 7 | 2011 | 960 | 0.140 |
Why?
|
DNA Repair | 1 | 2019 | 359 | 0.140 |
Why?
|
Alemtuzumab | 7 | 2011 | 85 | 0.140 |
Why?
|
Health Planning Guidelines | 1 | 2016 | 22 | 0.140 |
Why?
|
Gene Silencing | 3 | 2012 | 178 | 0.140 |
Why?
|
Gene Expression Regulation, Developmental | 2 | 2011 | 659 | 0.140 |
Why?
|
Tretinoin | 2 | 2018 | 128 | 0.140 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2016 | 19 | 0.140 |
Why?
|
Succinic Acid | 1 | 2015 | 7 | 0.140 |
Why?
|
Haploidy | 1 | 2016 | 32 | 0.140 |
Why?
|
Paramyxoviridae | 1 | 2015 | 10 | 0.140 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2015 | 5 | 0.140 |
Why?
|
Fumarates | 1 | 2015 | 19 | 0.130 |
Why?
|
Leukemia, Radiation-Induced | 1 | 2015 | 14 | 0.130 |
Why?
|
Enhancer Elements, Genetic | 2 | 2015 | 280 | 0.130 |
Why?
|
Mice, Nude | 2 | 2021 | 814 | 0.130 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2019 | 440 | 0.130 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2014 | 2399 | 0.130 |
Why?
|
Melphalan | 3 | 2011 | 98 | 0.130 |
Why?
|
Glycine | 1 | 2016 | 94 | 0.130 |
Why?
|
Cells, Cultured | 3 | 2021 | 2879 | 0.130 |
Why?
|
Lymphocyte Depletion | 2 | 2017 | 98 | 0.130 |
Why?
|
Cytidine Deaminase | 1 | 2015 | 43 | 0.130 |
Why?
|
Community-Acquired Infections | 1 | 2015 | 64 | 0.130 |
Why?
|
Protein Isoforms | 3 | 2013 | 273 | 0.130 |
Why?
|
Models, Molecular | 4 | 2015 | 1295 | 0.130 |
Why?
|
Patients | 1 | 2016 | 102 | 0.130 |
Why?
|
Age Factors | 6 | 2018 | 1863 | 0.130 |
Why?
|
Survival Rate | 7 | 2014 | 1883 | 0.130 |
Why?
|
Mitochondria | 1 | 2019 | 552 | 0.130 |
Why?
|
Ascorbic Acid | 1 | 2015 | 38 | 0.130 |
Why?
|
WT1 Proteins | 1 | 2014 | 20 | 0.130 |
Why?
|
Genetic Diseases, Inborn | 1 | 2015 | 101 | 0.130 |
Why?
|
Respiratory Tract Infections | 1 | 2015 | 107 | 0.130 |
Why?
|
Histone-Lysine N-Methyltransferase | 2 | 2013 | 159 | 0.120 |
Why?
|
Ureter | 1 | 1996 | 93 | 0.120 |
Why?
|
Antigens, Surface | 1 | 2015 | 103 | 0.120 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2019 | 589 | 0.120 |
Why?
|
Vidarabine | 3 | 2010 | 143 | 0.120 |
Why?
|
Triazoles | 1 | 2015 | 100 | 0.120 |
Why?
|
Hydroxamic Acids | 1 | 2014 | 51 | 0.120 |
Why?
|
Folic Acid | 1 | 2015 | 63 | 0.120 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2020 | 354 | 0.120 |
Why?
|
Case-Control Studies | 3 | 2015 | 1851 | 0.120 |
Why?
|
Graft Survival | 3 | 2016 | 916 | 0.120 |
Why?
|
Microfluidics | 1 | 2015 | 52 | 0.120 |
Why?
|
Immunophenotyping | 1 | 2015 | 217 | 0.120 |
Why?
|
Disease-Free Survival | 6 | 2016 | 1213 | 0.120 |
Why?
|
Apoptosis | 4 | 2013 | 1718 | 0.120 |
Why?
|
Pancreatic Neoplasms | 2 | 2017 | 659 | 0.120 |
Why?
|
Response Elements | 1 | 2014 | 65 | 0.120 |
Why?
|
Infant | 4 | 2024 | 3117 | 0.120 |
Why?
|
Structure-Activity Relationship | 1 | 2015 | 411 | 0.120 |
Why?
|
Child, Preschool | 4 | 2024 | 3678 | 0.110 |
Why?
|
Disease Progression | 4 | 2016 | 1490 | 0.110 |
Why?
|
DNA, Neoplasm | 2 | 2013 | 269 | 0.110 |
Why?
|
Histocompatibility Antigens | 1 | 2013 | 38 | 0.110 |
Why?
|
Fluorescent Antibody Technique | 3 | 2021 | 324 | 0.110 |
Why?
|
Glucocorticoids | 1 | 2015 | 358 | 0.110 |
Why?
|
Retrospective Studies | 9 | 2022 | 8893 | 0.110 |
Why?
|
Protein Structure, Tertiary | 2 | 2015 | 741 | 0.110 |
Why?
|
Blood Grouping and Crossmatching | 1 | 2012 | 13 | 0.110 |
Why?
|
Antigens, CD | 1 | 2015 | 466 | 0.110 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 156 | 0.110 |
Why?
|
Drug Administration Schedule | 4 | 2018 | 902 | 0.110 |
Why?
|
Karyotyping | 2 | 2011 | 253 | 0.110 |
Why?
|
Cerebellum | 2 | 2011 | 249 | 0.110 |
Why?
|
Homeostasis | 2 | 2012 | 408 | 0.110 |
Why?
|
California | 2 | 2024 | 143 | 0.110 |
Why?
|
Incidence | 5 | 2021 | 1592 | 0.110 |
Why?
|
Point Mutation | 2 | 2012 | 246 | 0.110 |
Why?
|
Quantitative Trait, Heritable | 1 | 2013 | 124 | 0.100 |
Why?
|
Chromatin | 1 | 2015 | 396 | 0.100 |
Why?
|
Hemagglutinins, Viral | 1 | 1992 | 38 | 0.100 |
Why?
|
Genes, BRCA1 | 2 | 2015 | 192 | 0.100 |
Why?
|
Imatinib Mesylate | 2 | 2009 | 127 | 0.100 |
Why?
|
Membrane Fusion | 1 | 1992 | 37 | 0.100 |
Why?
|
Phosphorylation | 2 | 2019 | 1129 | 0.100 |
Why?
|
Viral Envelope Proteins | 1 | 1992 | 95 | 0.100 |
Why?
|
Myelopoiesis | 1 | 2011 | 10 | 0.100 |
Why?
|
Infant, Newborn | 3 | 2024 | 2445 | 0.100 |
Why?
|
Diet | 1 | 2015 | 442 | 0.100 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2012 | 125 | 0.100 |
Why?
|
Glioblastoma | 1 | 2014 | 265 | 0.100 |
Why?
|
Comorbidity | 4 | 2018 | 947 | 0.100 |
Why?
|
Dinucleoside Phosphates | 1 | 2011 | 9 | 0.100 |
Why?
|
Benzamides | 2 | 2009 | 239 | 0.100 |
Why?
|
Leukocyte Transfusion | 1 | 2010 | 15 | 0.100 |
Why?
|
Carbazoles | 1 | 2011 | 33 | 0.090 |
Why?
|
Graft vs Tumor Effect | 1 | 2010 | 25 | 0.090 |
Why?
|
Genome-Wide Association Study | 3 | 2017 | 1662 | 0.090 |
Why?
|
Biotin | 1 | 2010 | 45 | 0.090 |
Why?
|
Hepatic Veno-Occlusive Disease | 1 | 2010 | 19 | 0.090 |
Why?
|
Busulfan | 1 | 2010 | 41 | 0.090 |
Why?
|
Catalytic Domain | 1 | 2011 | 157 | 0.090 |
Why?
|
DNA Mismatch Repair | 1 | 2010 | 55 | 0.090 |
Why?
|
Codon, Nonsense | 1 | 2010 | 42 | 0.090 |
Why?
|
Kidney | 1 | 1996 | 1145 | 0.090 |
Why?
|
Piperazines | 2 | 2009 | 280 | 0.090 |
Why?
|
Staining and Labeling | 1 | 2010 | 167 | 0.090 |
Why?
|
Salvage Therapy | 2 | 2011 | 235 | 0.090 |
Why?
|
Family Health | 1 | 2010 | 162 | 0.090 |
Why?
|
Substrate Specificity | 1 | 2011 | 352 | 0.090 |
Why?
|
Microfilament Proteins | 3 | 2001 | 212 | 0.090 |
Why?
|
Graft Rejection | 1 | 2016 | 1083 | 0.090 |
Why?
|
Precancerous Conditions | 1 | 2011 | 200 | 0.090 |
Why?
|
Oligodeoxyribonucleotides | 2 | 2008 | 127 | 0.090 |
Why?
|
Neutropenia | 1 | 2010 | 216 | 0.090 |
Why?
|
Transplantation Chimera | 1 | 2009 | 81 | 0.090 |
Why?
|
Tissue Distribution | 3 | 2000 | 292 | 0.090 |
Why?
|
Crystallography, X-Ray | 1 | 2011 | 487 | 0.090 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2009 | 44 | 0.080 |
Why?
|
Cohort Studies | 2 | 2014 | 2837 | 0.080 |
Why?
|
Polymorphism, Genetic | 1 | 2013 | 825 | 0.080 |
Why?
|
Transfer RNA Aminoacylation | 1 | 2009 | 19 | 0.080 |
Why?
|
Proteasome Inhibitors | 1 | 2009 | 52 | 0.080 |
Why?
|
Sequence Homology, Amino Acid | 3 | 2015 | 418 | 0.080 |
Why?
|
Boronic Acids | 1 | 2009 | 56 | 0.080 |
Why?
|
Protease Inhibitors | 1 | 2009 | 74 | 0.080 |
Why?
|
Neoplasm Staging | 4 | 2018 | 1983 | 0.080 |
Why?
|
Outpatients | 1 | 2009 | 98 | 0.080 |
Why?
|
Leukemia, Mast-Cell | 1 | 2008 | 5 | 0.080 |
Why?
|
Proportional Hazards Models | 4 | 2016 | 858 | 0.080 |
Why?
|
Prospective Studies | 5 | 2023 | 4271 | 0.080 |
Why?
|
Kruppel-Like Factor 6 | 1 | 2008 | 5 | 0.080 |
Why?
|
Pyrazines | 1 | 2009 | 94 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2012 | 294 | 0.080 |
Why?
|
Heart | 1 | 2012 | 572 | 0.080 |
Why?
|
RNA, Neoplasm | 1 | 2008 | 88 | 0.080 |
Why?
|
Thionucleotides | 1 | 2008 | 56 | 0.080 |
Why?
|
Blood Component Removal | 1 | 2008 | 24 | 0.080 |
Why?
|
Quinoxalines | 1 | 2008 | 50 | 0.080 |
Why?
|
Hippocampus | 1 | 2011 | 446 | 0.080 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2008 | 98 | 0.080 |
Why?
|
Sequence Deletion | 1 | 2008 | 205 | 0.080 |
Why?
|
C-Reactive Protein | 1 | 2008 | 195 | 0.080 |
Why?
|
Genome | 1 | 2010 | 385 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2011 | 308 | 0.070 |
Why?
|
Amino Acid Sequence | 4 | 2015 | 2062 | 0.070 |
Why?
|
RNA, Transfer | 1 | 2009 | 159 | 0.070 |
Why?
|
Maximum Tolerated Dose | 3 | 2014 | 272 | 0.070 |
Why?
|
Adenosine Triphosphate | 1 | 2008 | 315 | 0.070 |
Why?
|
Tumor Cells, Cultured | 3 | 2020 | 1057 | 0.070 |
Why?
|
Mycoses | 1 | 2007 | 46 | 0.070 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 176 | 0.070 |
Why?
|
Transplantation, Haploidentical | 2 | 2017 | 27 | 0.070 |
Why?
|
Karnofsky Performance Status | 1 | 2006 | 40 | 0.070 |
Why?
|
Leukocytes | 1 | 2007 | 203 | 0.070 |
Why?
|
Real-Time Polymerase Chain Reaction | 2 | 2021 | 282 | 0.070 |
Why?
|
Radiotherapy | 1 | 2008 | 331 | 0.070 |
Why?
|
Ganciclovir | 1 | 2006 | 49 | 0.070 |
Why?
|
Flow Cytometry | 2 | 2021 | 691 | 0.070 |
Why?
|
Valine | 1 | 2006 | 62 | 0.070 |
Why?
|
Leukocyte Count | 2 | 2016 | 222 | 0.070 |
Why?
|
Acyclovir | 1 | 2006 | 107 | 0.070 |
Why?
|
Introns | 2 | 2013 | 298 | 0.060 |
Why?
|
Caenorhabditis elegans | 1 | 2007 | 229 | 0.060 |
Why?
|
Lung | 1 | 2012 | 1243 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 1039 | 0.060 |
Why?
|
Cloning, Molecular | 2 | 2012 | 647 | 0.060 |
Why?
|
Cytomegalovirus Infections | 1 | 2006 | 147 | 0.060 |
Why?
|
Bone Marrow Transplantation | 1 | 2006 | 283 | 0.060 |
Why?
|
Registries | 2 | 2021 | 759 | 0.060 |
Why?
|
Blotting, Western | 2 | 2021 | 797 | 0.060 |
Why?
|
DNA Primers | 3 | 2002 | 543 | 0.060 |
Why?
|
Lymphocyte Activation | 2 | 2019 | 747 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 603 | 0.060 |
Why?
|
Conserved Sequence | 2 | 2015 | 211 | 0.060 |
Why?
|
Transcriptome | 2 | 2020 | 623 | 0.060 |
Why?
|
Microarray Analysis | 2 | 2015 | 96 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2013 | 697 | 0.060 |
Why?
|
Polymorphism, Single-Stranded Conformational | 2 | 2000 | 28 | 0.060 |
Why?
|
Morbidity | 1 | 2023 | 149 | 0.060 |
Why?
|
Immunotherapy | 1 | 2009 | 661 | 0.060 |
Why?
|
Methylation | 2 | 2015 | 267 | 0.050 |
Why?
|
Polycomb Repressive Complex 2 | 1 | 2022 | 32 | 0.050 |
Why?
|
Enzyme Activation | 2 | 2021 | 698 | 0.050 |
Why?
|
Doxorubicin | 2 | 2013 | 298 | 0.050 |
Why?
|
World Health Organization | 1 | 2022 | 104 | 0.050 |
Why?
|
Porosity | 2 | 2015 | 60 | 0.050 |
Why?
|
Cytogenetics | 1 | 2021 | 27 | 0.050 |
Why?
|
Benzothiazoles | 1 | 2021 | 17 | 0.050 |
Why?
|
Gene Regulatory Networks | 2 | 2017 | 307 | 0.050 |
Why?
|
Antiviral Agents | 1 | 2006 | 515 | 0.050 |
Why?
|
Polymerase Chain Reaction | 3 | 2013 | 927 | 0.050 |
Why?
|
Syndrome | 1 | 2022 | 448 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2019 | 2746 | 0.050 |
Why?
|
HeLa Cells | 2 | 2015 | 507 | 0.050 |
Why?
|
Naphthyridines | 1 | 2021 | 27 | 0.050 |
Why?
|
Heterozygote | 1 | 2022 | 372 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 196 | 0.050 |
Why?
|
Physical Chromosome Mapping | 1 | 2001 | 27 | 0.050 |
Why?
|
Drug Synergism | 1 | 2021 | 305 | 0.050 |
Why?
|
Muscle Hypotonia | 1 | 2021 | 45 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 891 | 0.050 |
Why?
|
Microcephaly | 1 | 2021 | 76 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2021 | 3655 | 0.050 |
Why?
|
Illinois | 2 | 2012 | 465 | 0.050 |
Why?
|
Animals, Newborn | 2 | 2012 | 523 | 0.050 |
Why?
|
Chromosome Breakage | 1 | 2020 | 17 | 0.040 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2020 | 86 | 0.040 |
Why?
|
Carrier Proteins | 2 | 2001 | 679 | 0.040 |
Why?
|
Connectin | 1 | 1999 | 5 | 0.040 |
Why?
|
Cell Lineage | 2 | 2011 | 291 | 0.040 |
Why?
|
Methyltransferases | 1 | 2021 | 192 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2022 | 774 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2015 | 1020 | 0.040 |
Why?
|
Molecular Dynamics Simulation | 1 | 2021 | 249 | 0.040 |
Why?
|
Molecular Weight | 1 | 1999 | 332 | 0.040 |
Why?
|
Developmental Disabilities | 1 | 2021 | 202 | 0.040 |
Why?
|
Mammary Tumor Virus, Mouse | 2 | 1996 | 64 | 0.040 |
Why?
|
Repetitive Sequences, Nucleic Acid | 2 | 1996 | 135 | 0.040 |
Why?
|
Quality of Life | 1 | 2007 | 1649 | 0.040 |
Why?
|
Consolidation Chemotherapy | 1 | 2018 | 23 | 0.040 |
Why?
|
DNA, Complementary | 1 | 1999 | 392 | 0.040 |
Why?
|
Expert Testimony | 1 | 2018 | 46 | 0.040 |
Why?
|
Motor Activity | 1 | 2021 | 328 | 0.040 |
Why?
|
Aneuploidy | 2 | 1996 | 57 | 0.040 |
Why?
|
Lactobacillus | 1 | 2018 | 21 | 0.040 |
Why?
|
Paraproteins | 1 | 2018 | 6 | 0.040 |
Why?
|
Hydrogen Peroxide | 1 | 2019 | 159 | 0.040 |
Why?
|
Wnt Proteins | 5 | 1997 | 130 | 0.040 |
Why?
|
Disease Models, Animal | 3 | 2015 | 2346 | 0.040 |
Why?
|
Cyclin D2 | 1 | 2018 | 19 | 0.040 |
Why?
|
Cluster Analysis | 2 | 2011 | 371 | 0.040 |
Why?
|
Maintenance Chemotherapy | 1 | 2018 | 80 | 0.040 |
Why?
|
Cytoskeletal Proteins | 1 | 1999 | 227 | 0.040 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2018 | 5 | 0.040 |
Why?
|
Preoperative Period | 1 | 2018 | 94 | 0.040 |
Why?
|
Permeability | 1 | 2018 | 137 | 0.040 |
Why?
|
Germ-Free Life | 1 | 2018 | 75 | 0.040 |
Why?
|
Toll-Like Receptor 2 | 1 | 2018 | 35 | 0.040 |
Why?
|
Immunosuppressive Agents | 2 | 2015 | 994 | 0.040 |
Why?
|
Superoxide Dismutase | 1 | 2019 | 177 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2009 | 430 | 0.040 |
Why?
|
United States | 2 | 2021 | 6882 | 0.040 |
Why?
|
Oxidation-Reduction | 1 | 2019 | 385 | 0.040 |
Why?
|
Central Nervous System Neoplasms | 1 | 2018 | 85 | 0.040 |
Why?
|
Patient-Specific Modeling | 1 | 2017 | 20 | 0.040 |
Why?
|
Plasma Cells | 1 | 2018 | 82 | 0.040 |
Why?
|
Radiation Exposure | 1 | 2017 | 24 | 0.040 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2017 | 79 | 0.040 |
Why?
|
Cause of Death | 1 | 2018 | 270 | 0.040 |
Why?
|
Neoplasm Grading | 1 | 2018 | 367 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2007 | 2285 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 2017 | 397 | 0.040 |
Why?
|
Transfection | 2 | 2010 | 914 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2014 | 1709 | 0.040 |
Why?
|
Databases, Nucleic Acid | 1 | 2016 | 41 | 0.040 |
Why?
|
Bacterial Infections | 1 | 2018 | 184 | 0.030 |
Why?
|
Blood Urea Nitrogen | 1 | 1996 | 33 | 0.030 |
Why?
|
Gene Knock-In Techniques | 1 | 2016 | 29 | 0.030 |
Why?
|
Texas | 1 | 2016 | 108 | 0.030 |
Why?
|
Leukemic Infiltration | 1 | 2015 | 14 | 0.030 |
Why?
|
Chimerism | 1 | 2016 | 37 | 0.030 |
Why?
|
Histocompatibility | 1 | 2016 | 66 | 0.030 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2015 | 34 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2019 | 457 | 0.030 |
Why?
|
Bone Marrow Diseases | 1 | 2015 | 40 | 0.030 |
Why?
|
Workflow | 1 | 2016 | 79 | 0.030 |
Why?
|
Antigens, Differentiation | 1 | 1996 | 141 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 1996 | 312 | 0.030 |
Why?
|
Mesoderm | 1 | 1996 | 124 | 0.030 |
Why?
|
Gene Deletion | 2 | 2011 | 342 | 0.030 |
Why?
|
Surveys and Questionnaires | 1 | 2023 | 2593 | 0.030 |
Why?
|
Genomic Instability | 1 | 2015 | 79 | 0.030 |
Why?
|
Drosophila Proteins | 1 | 2000 | 498 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 1096 | 0.030 |
Why?
|
Europe | 1 | 2016 | 314 | 0.030 |
Why?
|
Organ Size | 1 | 1996 | 369 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 24 | 0.030 |
Why?
|
Mortality | 1 | 2016 | 150 | 0.030 |
Why?
|
Proto-Oncogenes | 2 | 2010 | 61 | 0.030 |
Why?
|
Cell Division | 2 | 2011 | 696 | 0.030 |
Why?
|
MCF-7 Cells | 1 | 2015 | 114 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 80 | 0.030 |
Why?
|
Neutrophils | 1 | 2016 | 308 | 0.030 |
Why?
|
Transplant Recipients | 1 | 2015 | 139 | 0.030 |
Why?
|
Genes, Reporter | 1 | 2015 | 275 | 0.030 |
Why?
|
Cocarcinogenesis | 1 | 1994 | 12 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 1996 | 565 | 0.030 |
Why?
|
Genetics, Medical | 1 | 2014 | 52 | 0.030 |
Why?
|
Cadherins | 1 | 2015 | 162 | 0.030 |
Why?
|
Chromosome Mapping | 2 | 2011 | 1077 | 0.030 |
Why?
|
Survivors | 1 | 2015 | 233 | 0.030 |
Why?
|
Smad1 Protein | 1 | 2013 | 3 | 0.030 |
Why?
|
Glycosyltransferases | 1 | 2013 | 19 | 0.030 |
Why?
|
Caspase 8 | 1 | 2013 | 34 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 2013 | 231 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2015 | 141 | 0.030 |
Why?
|
Computational Biology | 1 | 2016 | 542 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2013 | 119 | 0.030 |
Why?
|
Immunoglobulin Isotypes | 1 | 2013 | 31 | 0.030 |
Why?
|
Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
Cyclin D1 | 1 | 2013 | 84 | 0.030 |
Why?
|
Referral and Consultation | 1 | 2016 | 342 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 2013 | 61 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 2018 | 804 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 66 | 0.030 |
Why?
|
Caspase 3 | 1 | 2013 | 161 | 0.030 |
Why?
|
beta Catenin | 1 | 2015 | 266 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2013 | 98 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2015 | 1086 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 575 | 0.030 |
Why?
|
Epistasis, Genetic | 1 | 2013 | 89 | 0.030 |
Why?
|
Wnt1 Protein | 3 | 1997 | 25 | 0.030 |
Why?
|
Virus Diseases | 1 | 2013 | 97 | 0.030 |
Why?
|
Bromelains | 1 | 1992 | 1 | 0.030 |
Why?
|
Inflammation | 1 | 2018 | 961 | 0.030 |
Why?
|
Databases, Genetic | 1 | 2013 | 263 | 0.030 |
Why?
|
Binding Sites, Antibody | 1 | 1992 | 49 | 0.030 |
Why?
|
Trypsin | 1 | 1992 | 95 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2012 | 25 | 0.030 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1992 | 70 | 0.030 |
Why?
|
Methyl-CpG-Binding Protein 2 | 1 | 2011 | 17 | 0.030 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2011 | 41 | 0.030 |
Why?
|
Erythrocytes | 1 | 2013 | 254 | 0.030 |
Why?
|
Sulfites | 1 | 2012 | 30 | 0.030 |
Why?
|
Quinazolines | 1 | 2013 | 221 | 0.030 |
Why?
|
Validation Studies as Topic | 1 | 2011 | 16 | 0.020 |
Why?
|
Rett Syndrome | 1 | 2011 | 19 | 0.020 |
Why?
|
Kidney Failure, Chronic | 1 | 1996 | 414 | 0.020 |
Why?
|
Adult Stem Cells | 1 | 2011 | 29 | 0.020 |
Why?
|
Colony-Forming Units Assay | 1 | 2011 | 40 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2012 | 127 | 0.020 |
Why?
|
Granulocytes | 1 | 2011 | 38 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2011 | 139 | 0.020 |
Why?
|
DNA Damage | 1 | 2013 | 371 | 0.020 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1992 | 283 | 0.020 |
Why?
|
Core Binding Factors | 1 | 2011 | 12 | 0.020 |
Why?
|
Lentivirus | 1 | 2011 | 43 | 0.020 |
Why?
|
Sheep | 1 | 2011 | 250 | 0.020 |
Why?
|
Gene Knockout Techniques | 1 | 2011 | 82 | 0.020 |
Why?
|
Furans | 1 | 2011 | 16 | 0.020 |
Why?
|
CCCTC-Binding Factor | 1 | 2011 | 18 | 0.020 |
Why?
|
X Chromosome | 1 | 2011 | 153 | 0.020 |
Why?
|
Cricetinae | 1 | 1992 | 560 | 0.020 |
Why?
|
MDS1 and EVI1 Complex Locus Protein | 1 | 2010 | 6 | 0.020 |
Why?
|
Hydroxylation | 1 | 2010 | 17 | 0.020 |
Why?
|
Bacteriophage T4 | 1 | 2010 | 9 | 0.020 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 27 | 0.020 |
Why?
|
GATA1 Transcription Factor | 1 | 2010 | 18 | 0.020 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2011 | 72 | 0.020 |
Why?
|
Glucosyltransferases | 1 | 2010 | 25 | 0.020 |
Why?
|
Diarrhea | 1 | 2012 | 182 | 0.020 |
Why?
|
Genes, ras | 1 | 2011 | 98 | 0.020 |
Why?
|
Organ Specificity | 1 | 2011 | 272 | 0.020 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2010 | 71 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1992 | 499 | 0.020 |
Why?
|
Protein Binding | 1 | 2014 | 1484 | 0.020 |
Why?
|
Metabolic Clearance Rate | 1 | 2010 | 120 | 0.020 |
Why?
|
Mutant Proteins | 1 | 2011 | 95 | 0.020 |
Why?
|
Thrombospondin 1 | 1 | 2010 | 21 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2013 | 389 | 0.020 |
Why?
|
Valproic Acid | 1 | 2010 | 24 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2011 | 279 | 0.020 |
Why?
|
Stem Cells | 1 | 2013 | 371 | 0.020 |
Why?
|
Drug Combinations | 1 | 2010 | 203 | 0.020 |
Why?
|
Acetylation | 1 | 2010 | 132 | 0.020 |
Why?
|
Models, Animal | 1 | 2011 | 276 | 0.020 |
Why?
|
Cell Shape | 1 | 2010 | 51 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2010 | 136 | 0.020 |
Why?
|
Monocytes | 1 | 2011 | 217 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2011 | 446 | 0.020 |
Why?
|
CD3 Complex | 1 | 2009 | 134 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2011 | 902 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2011 | 262 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2011 | 479 | 0.020 |
Why?
|
Bortezomib | 1 | 2009 | 82 | 0.020 |
Why?
|
Protein Conformation | 1 | 1992 | 884 | 0.020 |
Why?
|
Down-Regulation | 1 | 2010 | 520 | 0.020 |
Why?
|
Myeloablative Agonists | 1 | 2008 | 36 | 0.020 |
Why?
|
Pilot Projects | 1 | 2011 | 866 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2010 | 637 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2001 | 311 | 0.020 |
Why?
|
Half-Life | 1 | 2008 | 96 | 0.020 |
Why?
|
Stereoisomerism | 1 | 2008 | 102 | 0.020 |
Why?
|
Filgrastim | 1 | 2008 | 57 | 0.020 |
Why?
|
Tacrolimus | 1 | 2009 | 374 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2008 | 71 | 0.020 |
Why?
|
Signal Transduction | 1 | 2019 | 3368 | 0.020 |
Why?
|
Molecular Structure | 1 | 2008 | 289 | 0.020 |
Why?
|
Protein Transport | 1 | 2009 | 419 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2013 | 1843 | 0.020 |
Why?
|
Protein Biosynthesis | 1 | 2009 | 391 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 2008 | 289 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2008 | 342 | 0.020 |
Why?
|
Antifungal Agents | 1 | 2007 | 119 | 0.020 |
Why?
|
Hyperplasia | 2 | 1997 | 152 | 0.020 |
Why?
|
Crosses, Genetic | 2 | 1997 | 171 | 0.020 |
Why?
|
Mammary Glands, Animal | 2 | 1997 | 80 | 0.020 |
Why?
|
Liver Diseases | 1 | 2008 | 250 | 0.020 |
Why?
|
Rats | 1 | 2012 | 4041 | 0.020 |
Why?
|
Length of Stay | 1 | 2008 | 726 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 2019 | 0.010 |
Why?
|
Chromosomes, Artificial, Human | 1 | 2001 | 2 | 0.010 |
Why?
|
Apc8 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2001 | 2 | 0.010 |
Why?
|
Nuclear Localization Signals | 1 | 2000 | 10 | 0.010 |
Why?
|
Gene Library | 1 | 2001 | 133 | 0.010 |
Why?
|
Time Factors | 1 | 2009 | 5319 | 0.010 |
Why?
|
Consensus Sequence | 1 | 2000 | 65 | 0.010 |
Why?
|
Tandem Repeat Sequences | 1 | 2000 | 27 | 0.010 |
Why?
|
Amino Acid Motifs | 1 | 2000 | 116 | 0.010 |
Why?
|
Open Reading Frames | 1 | 2000 | 119 | 0.010 |
Why?
|
Insect Proteins | 1 | 2000 | 88 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2000 | 353 | 0.010 |
Why?
|
Mitosis | 1 | 1997 | 152 | 0.010 |
Why?
|
RNA Polymerase III | 1 | 1996 | 8 | 0.010 |
Why?
|
Mitogens | 1 | 1996 | 63 | 0.010 |
Why?
|
Drosophila | 1 | 2000 | 511 | 0.010 |
Why?
|
Gene Targeting | 1 | 1996 | 73 | 0.010 |
Why?
|
Neoplasms, Experimental | 1 | 1996 | 269 | 0.010 |
Why?
|
Fibrosis | 1 | 1995 | 237 | 0.010 |
Why?
|
Fibroblast Growth Factors | 1 | 1994 | 81 | 0.010 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 1994 | 162 | 0.010 |
Why?
|